Deep Dive: DOACs in 2026: Why the Incumbents Still Win

Generated August 2026 · Clinical Deep Dive0 CommentsTwo consecutive late-stage trials set out to do what a decade of drug development had not: dislodge apixaban, rivaroxaban, dabigatran, and edoxaban from their position as the default oral anticoagulants for stroke prevention and venous thromboembolism (VTE). Both failed to deliver a clean win. In the phase 3, 14,810-patient OCEANIC-AF trial, the factor XIa inhibitor asundexian was stopped early by the independent data monitoring committee after stroke or systemic embolism occurred in 1.3% of patients assigned to asundexian versus 0.4% assigned to apixaban (hazard ratio 3.79, 95% CI 2.46-5.83), despite asundexian producing markedly less major bleeding (0.2% vs 0.7%; hazard ratio 0.32, 95% CI 0.18-0.55). N Engl J MedThe monoclonal antibody abelacimab fared better on safety: in the 1287-patient AZALEA-TIMI 71 trial, monthly subcutaneous abelacimab reduced major or clinically relevant nonmajor bleeding versus rivaroxaban in AF by 62% at the 150-mg dose and 69% at the 90-mg dose (hazard ratio 0.38 and 0.31, respectively; both P<0.001), but the trial was stopped early for that bleeding benefit, before its small, hypothesis-generating stroke data could establish comparable or superior stroke prevention. N Engl J MedThe net effect: apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) remain the only direct oral anticoagulants (DOACs) approved in the United States for routine anticoagulation, a four-agent roster unchanged since edoxaban's approval in 2015. DailyMed Savaysa All four still carry the class-defining boxed warning that abrupt discontinuation increases thrombotic risk and that spinal or epidural hematoma can occur with neuraxial procedures. FDA Eliquis PI +3Underneath that clinical stability, the commercial ground is shifting for the first time. The FDA approved the first generic rivaroxaban 2.5-mg tablets in March 2025, while patent litigation blocks generic apixaban from the US market until at least April 1, 2028. Pharmacy Times For a class that has otherwise been managed as four largely interchangeable options, this is the first meaningful price and access differential to open up between agents.For prescribers, the practical takeaway is that the four-agent framework that has governed anticoagulation since 2015 is not just durable, it is about to matter more: with efficacy differences that trials have consistently failed to demonstrate, renal cutoffs, reversal-agent availability, dosing frequency, and now acquisition cost are becoming the real axis of agent selection. This review works through mechanism, approved indications, pharmacokinetics, agent selection, safety, boxed warnings, drug interactions, special populations, monitoring, and the pipeline that just absorbed its most serious setback yet.At a Glance: Why the Incumbents Are Still Standing• OCEANIC-AF (asundexian vs apixaban, N=14,810 AF patients): stopped early by the independent data monitoring committee after stroke/systemic embolism occurred in 1.3% (asundexian) vs 0.4% (apixaban) (HR 3.79, 95% CI 2.46-5.83), despite less major bleeding with asundexian (0.2% vs 0.7%; HR 0.32, 95% CI 0.18-0.55). N Engl J Med• AZALEA-TIMI 71 (abelacimab vs rivaroxaban, AF, N=1287): stopped early after abelacimab cut major/clinically relevant nonmajor bleeding by 62%-69% vs rivaroxaban (HR 0.38 and 0.31, both P<0.001); stroke-prevention efficacy was not established before the trial's early termination. N Engl J Med• Generic rivaroxaban 2.5-mg tablets reached the US market in March 2025; generic apixaban remains blocked by patent settlements until April 1, 2028 at the earliest. Pharmacy TimesDEEP DIVE:Choosing and Managing DOAC Therapy in a Four-Agent, Unchallenged ClassMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: Four Drugs, No Successor: What a Decade of Failed Challengers Confirms About DOAC Therapy - Medscape- August 25, 2026.